Dr. Eggermont on Responses to Adjuvant Pembrolizumab in Stage III Melanoma Subtypes

Video

Alexander M. M. Eggermont, MD, PhD, discusses responses to adjuvant pembrolizumab in patients with different subtypes of stage III melanoma.

Alexander M. M. Eggermont, MD, PhD, professor of oncology, University of Paris-Sud, professor of oncological surgery, chair, International Research Network on Cancer, Erasmus University of Rotterdam, Joseph Maisin Honorary Chair of Oncological Surgery, Louvain Catholic University, discusses responses to adjuvant pembrolizumab (Keytruda) in patients with different subtypes of stage III melanoma.

Within stage III melanoma, there is stage IIIA disease, which encompasses microscopic lymph node involvement, IIIB disease, and IIIC disease, says Eggermont.

In updated findings from the phase 3 EORTC 1325-MG/KEYNOTE-054 trial, pembrolizumab (Keytruda) showed consistently better rates of recurrence-free survival (RFS) compared with placebo across stage III subtypes, explains Eggermont. Moreover, at a 3-year median follow-up, the hazard ratios with pembrolizumab were 0.50 in stage IIIA disease, 0.56 in IIIB disease, and 0.57 in IIIC disease. Additionally, RFS rates were 81.2%, 65.7%, and 54.3%, respectively.

These findings add to the discussion of whether pembrolizumab should be considered for patients with stage IIIA disease, concludes Eggermont.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,